Skip to main content

Sankyo Subscribes to LifeSpan Database

NEW YORK, July 24-The Japanese pharmaceutical company Sankyo has subscribed to the nuclear receptor module of LifeSpan BioScience's drug target database, LifeSpan said yesterday.


Sankyo will use the database to help in drug target validation for diseases like diabetes, cancer and obesity. It includes immunohistochemical data and public sequence and localization data on more than 2,000 genes.


LifeSpan's database includes information on gene families of interest for drug discovery, and has eight modules. Sankyo also subscribes to the company's G-protein coupled receptor database module.


Nuclear receptors regulate gene activity related to homeostasis, development and differentiation, and have been implicated in cancer, metabolic diseases, rheumatoid arthritis and other disorders.


LifeSpan BioScience is based in Seattle.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.